FDA Inspection 1205480 — Navinta, LLC
The FDA completed an inspection of Navinta, LLC on May 4, 2023 in Ewing, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- May 4, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Ewing, NJ (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)